Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Total Non-Current Liabilities (2021 - 2025)

Roivant Sciences' Total Non-Current Liabilities history spans 5 years, with the latest figure at $250.5 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 79.76% year-over-year to $250.5 million; the TTM value through Dec 2025 reached $250.5 million, down 79.76%, while the annual FY2025 figure was $18.4 million, 19.96% up from the prior year.
  • Total Non-Current Liabilities reached $250.5 million in Q4 2025 per ROIV's latest filing, down from $257.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $1.2 billion in Q4 2024 to a low of $15.4 million in Q1 2024.
  • Average Total Non-Current Liabilities over 5 years is $554.4 million, with a median of $612.6 million recorded in 2024.
  • The largest YoY upside for Total Non-Current Liabilities was 85.04% in 2024 against a maximum downside of 97.99% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $521.4 million in 2021, then soared by 44.66% to $754.3 million in 2022, then decreased by 11.36% to $668.6 million in 2023, then soared by 85.04% to $1.2 billion in 2024, then crashed by 79.76% to $250.5 million in 2025.
  • Per Business Quant, the three most recent readings for ROIV's Total Non-Current Liabilities are $250.5 million (Q4 2025), $257.0 million (Q3 2025), and $216.5 million (Q2 2025).